{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:38:20Z","timestamp":1782387500245,"version":"3.54.5"},"reference-count":36,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The current outbreak of novel coronavirus (COVID-19) infections urges the need to identify potential therapeutic agents. Therefore, the repurposing of FDA-approved drugs against today\u2019s diseases involves the use of de-risked compounds with potentially lower costs and shorter development timelines. In this study, the recently resolved X-ray crystallographic structure of COVID-19 main protease (Mpro) was used to generate a pharmacophore model and to conduct a docking study to capture antiviral drugs as new promising COVID-19 main protease inhibitors. The developed pharmacophore successfully captured five FDA-approved antiviral drugs (lopinavir, remdesivir, ritonavir, saquinavir and raltegravir). The five drugs were successfully docked into the binding site of COVID-19 Mpro and showed several specific binding interactions that were comparable to those tying the co-crystallized inhibitor X77 inside the binding site of COVID-19 Mpro. Three of the captured drugs namely, remdesivir, lopinavir and ritonavir, were reported to have promising results in COVID-19 treatment and therefore increases the confidence in our results. Our findings suggest an additional possible mechanism of action for remdesivir as an antiviral drug inhibiting COVID-19 Mpro. Additionally, a combination of structure-based pharmacophore modeling with a docking study is expected to facilitate the discovery of novel COVID-19 Mpro inhibitors.<\/jats:p>","DOI":"10.2478\/acph-2021-0016","type":"journal-article","created":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T02:17:05Z","timestamp":1611368225000},"page":"163-174","source":"Crossref","is-referenced-by-count":30,"title":["Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies"],"prefix":"10.2478","volume":"71","author":[{"given":"Safa","family":"Daoud","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical, Chemistry and Pharmacognosy, Faculty of Pharmacy, Applied Science , Private University , Amman , Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shada J.","family":"Alabed","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy , The University of Jordan , Amman , Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina A.","family":"Dahabiyeh","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy , The University of Jordan , Amman , Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2020,11,4]]},"reference":[{"key":"2026051108191116375_j_acph-2021-0016_ref_001_w2aab3b7c11b1b6b1ab1ab1Aa","doi-asserted-by":"crossref","unstructured":"1. N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, X. Zhao, B. Huang, W. Shi, R. Lu and P. Niu, A novel coronavirus from patients with pneumonia in China, 2019, N. Engl. J. Med. 382 (2020) 727\u2013733; https:\/\/doi.org\/10.1056\/NEJMoa200101710.1056\/NEJMoa2001017709280331978945","DOI":"10.1056\/NEJMoa2001017"},{"key":"2026051108191116375_j_acph-2021-0016_ref_002_w2aab3b7c11b1b6b1ab1ab2Aa","doi-asserted-by":"crossref","unstructured":"2. A. Zumla, J. F. Chan, E. I. Azhar, D. S. Hui and K. Y Yuen, Coronaviruses\u2014drug discovery and therapeutic options, Nat. Rev. Drug Discov. 15 (2016) 327\u2013347; https:\/\/doi.org\/10.1038\/nrd.2015.3710.1038\/nrd.2015.37709718126868298","DOI":"10.1038\/nrd.2015.37"},{"key":"2026051108191116375_j_acph-2021-0016_ref_003_w2aab3b7c11b1b6b1ab1ab3Aa","unstructured":"3. F. He, Y. Deng and W. Li, Coronavirus Disease 2019 (COVID-19): What we know? J. Med. Virol. (2020) (7 pages); https:\/\/doi.org\/10.1002\/jmv.2576610.1002\/jmv.25766722834032170865"},{"key":"2026051108191116375_j_acph-2021-0016_ref_004_w2aab3b7c11b1b6b1ab1ab4Aa","doi-asserted-by":"crossref","unstructured":"4. C. C. Lai, T. P. Shih, W. C. Ko, H. J. Tang and P. R. Hsueh, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges, Int. J. Antimicrob. Agents55 (2020) Article ID 105924; https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.10592410.1016\/j.ijantimicag.2020.105924712780032081636","DOI":"10.1016\/j.ijantimicag.2020.105924"},{"key":"2026051108191116375_j_acph-2021-0016_ref_005_w2aab3b7c11b1b6b1ab1ab5Aa","doi-asserted-by":"crossref","unstructured":"5. J. She, J. Jiang, L. Ye, L. Hu, C. Bai and Y. Song, 2019 Novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies, Clin.. Transl. Med.9 (2020) Article ID 19; https:\/\/doi.org\/10.1186\/s40169-020-00271-z10.1186\/s40169-020-00271-z703326332078069","DOI":"10.1186\/s40169-020-00271-z"},{"key":"2026051108191116375_j_acph-2021-0016_ref_006_w2aab3b7c11b1b6b1ab1ab6Aa","unstructured":"6. World Health Organization, Novel Coronavirus (Covid-19): Situation Report, 3. 2020, WHO, Geneve 2020; https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019?gclid=CjwKCAjwq832BRA5EiwACvCWsSQ_-qAh4z8Z5_gvnayDI2PrSx4poydPpu-pvDZX-k34RQDqn8TgEBoChdkQA-vD_BwE; last access date May 31, 2020"},{"key":"2026051108191116375_j_acph-2021-0016_ref_007_w2aab3b7c11b1b6b1ab1ab7Aa","doi-asserted-by":"crossref","unstructured":"7. H. A. Rothan and S. N. Byrareddy, The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak, J. Autoimmun.109 (2020) Article ID 102433 (4 pages); https:\/\/doi.org\/10.1016\/j.jaut.2020.10243310.1016\/j.jaut.2020.102433712706732113704","DOI":"10.1016\/j.jaut.2020.102433"},{"key":"2026051108191116375_j_acph-2021-0016_ref_008_w2aab3b7c11b1b6b1ab1ab8Aa","doi-asserted-by":"crossref","unstructured":"8. S. L. Senanayake, Drug repurposing strategies for COVID-19, Future Drug Discov.2 (2020) (3 pages); https:\/\/doi.org\/10.4155\/fdd-2020-001010.4155\/fdd-2020-0010","DOI":"10.4155\/fdd-2020-0010"},{"key":"2026051108191116375_j_acph-2021-0016_ref_009_w2aab3b7c11b1b6b1ab1ab9Aa","doi-asserted-by":"crossref","unstructured":"9. S. Pushpakom, F. Iorio, P. A. Eyers, K. J. Escott, S. Hopper, A. Wells, A. Doig, T. Guilliams, J. Latimer, C. McNamee and A. Norris, Drug repurposing: progress, challenges and recommendations, Nat. Rev. Drug Discov. 18 (2019) 41\u201358; https:\/\/doi.org\/10.1038\/nrd.2018.16810.1038\/nrd.2018.16830310233","DOI":"10.1038\/nrd.2018.168"},{"key":"2026051108191116375_j_acph-2021-0016_ref_010_w2aab3b7c11b1b6b1ab1ac10Aa","doi-asserted-by":"crossref","unstructured":"10. S. G. V. Rosa and W. C. Santos, Clinical trials on drug repositioning for COVID-19 treatment, Rev. Panam. Salud P\u00fabl. 44 (2020) e40; https:\/\/doi.org\/10.26633\/RPSP.2020.4010.26633\/RPSP.2020.40710528032256547","DOI":"10.26633\/RPSP.2020.40"},{"key":"2026051108191116375_j_acph-2021-0016_ref_011_w2aab3b7c11b1b6b1ab1ac11Aa","doi-asserted-by":"crossref","unstructured":"11. A. Gaurav, V. Gautam, S. Pereira, J. Alvarez-Leite, F. Vetri, M. Choudhury, D. Pelligrino, P. Sundivakkam, K. Radhakrishnan and A. Krieger, Structure-based three-dimensional pharmacophores as an alternative to traditional methodologies, J. Receptor Ligand Channel Res.7 (2014) 27\u201338; https:\/\/doi.org\/10.2147\/JRLCR.S4684510.2147\/JRLCR.S46845","DOI":"10.2147\/JRLCR.S46845"},{"key":"2026051108191116375_j_acph-2021-0016_ref_012_w2aab3b7c11b1b6b1ab1ac12Aa","doi-asserted-by":"crossref","unstructured":"12. M. P. Sanders, R. McGuire, L. Roumen, I. J. de Esch, J. de Vlieg, J. P. Klomp and C. de Graaf, From the protein\u2019s perspective: the benefits and challenges of protein structure-based pharmacophore modeling, MedChemComm.3 (2012) 28\u201338; https:\/\/doi.org\/10.1039\/C1MD00210D10.1039\/C1MD00210D","DOI":"10.1039\/C1MD00210D"},{"key":"2026051108191116375_j_acph-2021-0016_ref_013_w2aab3b7c11b1b6b1ab1ac13Aa","doi-asserted-by":"crossref","unstructured":"13. M. Wieder, U. Perricone, T. Seidel, S. Boresch and T. Langer, Comparing pharmacophore models derived from crystal structures and from molecular dynamics simulations, Monatsh. Chem. 147 (2016) 553\u2013563, https:\/\/doi.org\/10.1007\/s00706-016-1674-110.1007\/s00706-016-1674-1","DOI":"10.1007\/s00706-016-1674-1"},{"key":"2026051108191116375_j_acph-2021-0016_ref_014_w2aab3b7c11b1b6b1ab1ac14Aa","doi-asserted-by":"crossref","unstructured":"14. M. Arooj, S. Sakkiah, S. Kim, V. Arulalapperumal and K. W. Lee, A combination of receptor-based pharmacophore modeling & QM techniques for identification of human chymase inhibitors. PLoS One8 (2013) e63030; https:\/\/doi.org\/10.1371\/journal.pone.006303010.1371\/journal.pone.0063030","DOI":"10.1371\/journal.pone.0063030"},{"key":"2026051108191116375_j_acph-2021-0016_ref_015_w2aab3b7c11b1b6b1ab1ac15Aa","doi-asserted-by":"crossref","unstructured":"15. Z. Jin, X. Du, Y. Xu, Y. Deng, M. Liu, Y. Zhao, B. Zhang, X. Li, L. Zhang, C. Peng, Y. Duan, J. Yu, L. Wang, K. Yang, F. Liu, R. Jiang, X. Yang, T. You, X. Liu, X. Yang, F. Bai, H. Liu, X. Liu, L. W. Guddat, W. Xu, G. Xiao, C. Qin, Z. Shi, H. Jiang, Z. Rao and H. Yang: Structure of Mpro from SARSCoV-2 and discovery of its inhibitors, Nature5 (2020) (20 pages); https:\/\/doi.org\/10.1038\/s41586-020-2223-y10.1038\/s41586-020-2223-y","DOI":"10.1038\/s41586-020-2223-y"},{"key":"2026051108191116375_j_acph-2021-0016_ref_016_w2aab3b7c11b1b6b1ab1ac16Aa","doi-asserted-by":"crossref","unstructured":"16. L. A. Dahabiyeh, E. Y. Abu-rish and M. O. Taha, Inhibition of monoglyceride lipase by proton pump inhibitors: investigation using docking and in vitro experiments, Pharmacol. Rep.72 (2019) 435\u2013442; https:\/\/doi.org\/10.1007\/s43440-019-00013-010.1007\/s43440-019-00013-0","DOI":"10.1007\/s43440-019-00013-0"},{"key":"2026051108191116375_j_acph-2021-0016_ref_017_w2aab3b7c11b1b6b1ab1ac17Aa","doi-asserted-by":"crossref","unstructured":"17. L. A. Dahabiyeh, Y. Bustanji and M. O. Taha, The herbicide quinclorac as potent lipase inhibitor: Discovery via virtual screening and in vitro\/in vivo validation, Chem. Biol. Drug Des. 93 (2019) 787\u2013797; https:\/\/doi.org\/10.1111\/cbdd.1346310.1111\/cbdd.13463","DOI":"10.1111\/cbdd.13463"},{"key":"2026051108191116375_j_acph-2021-0016_ref_018_w2aab3b7c11b1b6b1ab1ac18Aa","doi-asserted-by":"crossref","unstructured":"18. D. J. Diller and K. M. Merz, Jr, High throughput docking for library design and library prioritization, Proteins43 (2001) 113\u2013124; https:\/\/doi.org\/10.1002\/1097-0134(20010501)43:2<113::aidprot1023>3.0.co;2-t","DOI":"10.1002\/1097-0134(20010501)43:2<113::AID-PROT1023>3.0.CO;2-T"},{"key":"2026051108191116375_j_acph-2021-0016_ref_019_w2aab3b7c11b1b6b1ab1ac19Aa","doi-asserted-by":"crossref","unstructured":"19. S. N. Rao, M. S. Head, A. Kulkarni and J. M. LaLonde, Validation studies of the site-directed docking program LibDock, J. Chem. Inf. Model.47 (2007) 2159\u20132171; https:\/\/doi.org\/10.1021\/ci600429910.1021\/ci6004299","DOI":"10.1021\/ci6004299"},{"key":"2026051108191116375_j_acph-2021-0016_ref_020_w2aab3b7c11b1b6b1ab1ac20Aa","doi-asserted-by":"crossref","unstructured":"20. A. N. Jain, Scoring noncovalent protein-ligand interactions: a continuous differentiable function tuned to compute binding affinities, J. Comput. Aided Mol. Des.10 (1996) 427\u2013440; https:\/\/doi.org\/10.1007\/BF0012447410.1007\/BF00124474","DOI":"10.1007\/BF00124474"},{"key":"2026051108191116375_j_acph-2021-0016_ref_021_w2aab3b7c11b1b6b1ab1ac21Aa","doi-asserted-by":"crossref","unstructured":"21. A. Krammer, P. D. Kirchhoff, X. Jiang, C. Venkatachalam and M. Waldman, LigScore: a novel scoring function for predicting binding affinities, J. Mol. Graph. Model. 23 (2005) 395\u2013407; https:\/\/doi.org\/10.1016\/j.jmgm.2004.11.00710.1016\/j.jmgm.2004.11.007","DOI":"10.1016\/j.jmgm.2004.11.007"},{"key":"2026051108191116375_j_acph-2021-0016_ref_022_w2aab3b7c11b1b6b1ab1ac22Aa","doi-asserted-by":"crossref","unstructured":"22. C. M. Venkatachalam, X. Jiang, T. Oldfield and M. Waldman, LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites, J. Mol. Graph. Model. 21 (2003) 289\u2013307; https:\/\/doi.org\/10.1016\/s1093-3263(02)00164-x10.1016\/S1093-3263(02)00164-X","DOI":"10.1016\/S1093-3263(02)00164-X"},{"key":"2026051108191116375_j_acph-2021-0016_ref_023_w2aab3b7c11b1b6b1ab1ac23Aa","doi-asserted-by":"crossref","unstructured":"23. D. K. Gehlhaar, D. Bouzida and P. A. Rejto, Reduced dimensionality in ligand-protein structure prediction: covalent inhibitors of serine proteases and design of site-directed combinatorial libraries, ACS Pub.719 (1999); https:\/\/doi.org\/10.1021\/bk-1999-0719.ch01910.1021\/bk-1999-0719.ch019","DOI":"10.1021\/bk-1999-0719.ch019"},{"key":"2026051108191116375_j_acph-2021-0016_ref_024_w2aab3b7c11b1b6b1ab1ac24Aa","doi-asserted-by":"crossref","unstructured":"24. I. Muegge, PMF scoring revisited, J. Med. Chem. 49 (2006) 5895\u20135902; https:\/\/doi.org\/10.1021\/jm050038s10.1021\/jm050038s17004705","DOI":"10.1021\/jm050038s"},{"key":"2026051108191116375_j_acph-2021-0016_ref_025_w2aab3b7c11b1b6b1ab1ac25Aa","doi-asserted-by":"crossref","unstructured":"25. I. Muegge and Y. C. Martin, A general and fast scoring function for protein-ligand interactions: a simplified potential approach, J. Med. Chem. 42 (1999) 791\u2013804; https:\/\/doi.org\/10.1021\/jm980536j10.1021\/jm980536j10072678","DOI":"10.1021\/jm980536j"},{"key":"2026051108191116375_j_acph-2021-0016_ref_026_w2aab3b7c11b1b6b1ab1ac26Aa","doi-asserted-by":"crossref","unstructured":"26. J. Wang, Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study, J. Chem. Inf. Model. (2020) (10 pages); https:\/\/doi.org\/10.1021\/acs.jcim.0c0017910.1021\/acs.jcim.0c00179719797232315171","DOI":"10.26434\/chemrxiv.11875446.v1"},{"key":"2026051108191116375_j_acph-2021-0016_ref_027_w2aab3b7c11b1b6b1ab1ac27Aa","doi-asserted-by":"crossref","unstructured":"27. A. Farag, P. Wang, M. Ahmed and H. Sadek, Identification of FDA approved drugs targeting COVID-19 virus by structure-based drug repositioning, ChemRxiv. (preprint) (2020); https:\/\/doi.org\/10.26434\/chemrxiv.12049647.v110.26434\/chemrxiv.12049647.v1","DOI":"10.26434\/chemrxiv.12003930.v2"},{"key":"2026051108191116375_j_acph-2021-0016_ref_028_w2aab3b7c11b1b6b1ab1ac28Aa","doi-asserted-by":"crossref","unstructured":"28. A. D. Mesecar (Center for Structural Genomics of Infectious Diseases, CSGID), A taxonomically-driven approach to development of potent, broad-spectrum inhibitors of coronavirus main pro-tease including SARS-CoV-2 (COVID-19), to be published; PDB ID 6W63, title: Structure of COVID-19 main protease bound to potent broad-spectrum non-covalent inhibitor X77, 2020; https:\/\/doi.org\/10.2210\/pdb6W63\/pdb10.2210\/pdb6w63\/pdb","DOI":"10.2210\/pdb6w63\/pdb"},{"key":"2026051108191116375_j_acph-2021-0016_ref_029_w2aab3b7c11b1b6b1ab1ac29Aa","unstructured":"29. J. Meslamani and D. Rognan, Protein-ligand pharmacophores: concept, design and applications, CICSJ Bull. 33 (2015) 27\u201332; https:\/\/doi.org\/10.11546\/cicsj.33.27"},{"key":"2026051108191116375_j_acph-2021-0016_ref_030_w2aab3b7c11b1b6b1ab1ac30Aa","doi-asserted-by":"crossref","unstructured":"30. L. Dong, S. Hu and J. Gao, Discovering drugs to treat coronavirus disease 2019 (COVID-19), Drug Discov. Ther.14 (2020) 58\u201360; https:\/\/doi.org\/10.5582\/ddt.2020.0101210.5582\/ddt.2020.0101232147628","DOI":"10.5582\/ddt.2020.01012"},{"key":"2026051108191116375_j_acph-2021-0016_ref_031_w2aab3b7c11b1b6b1ab1ac31Aa","doi-asserted-by":"crossref","unstructured":"31. E. P. Tchesnokov, J. Y. Feng, D. P. Porter and M. G\u00f6tte, Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir, Viruses11 (2019) Article ID 326; https:\/\/doi.org\/10.3390\/v1104032610.3390\/v11040326652071930987343","DOI":"10.3390\/v11040326"},{"key":"2026051108191116375_j_acph-2021-0016_ref_032_w2aab3b7c11b1b6b1ab1ac32Aa","doi-asserted-by":"crossref","unstructured":"32. J. A. Al-Tawfiq, A. H. Al-Homoud and Z. A. Memish, Remdesivir as a possible therapeutic option for the COVID-19, Travel. Med. Infect. Dis.34 (2020) Article ID 101615; https:\/\/doi.org\/10.1016\/j.tmaid.2020.10161510.1016\/j.tmaid.2020.101615712939132145386","DOI":"10.1016\/j.tmaid.2020.101615"},{"key":"2026051108191116375_j_acph-2021-0016_ref_033_w2aab3b7c11b1b6b1ab1ac33Aa","doi-asserted-by":"crossref","unstructured":"33. T. Stankovi\u0107, J. Dini\u0107, A. Podolski-Reni\u0107, L. Musso, S. S. Buri\u0107, S. Dallavalle and M. Pe\u0161i\u0107, Dual inhibitors as a new challenge for cancer multidrug resistance treatment, Curr. Med. Chem.26 (2019) 6074\u20136106; https:\/\/doi.org\/10.2174\/092986732566618060709485610.2174\/092986732566618060709485629874992","DOI":"10.2174\/0929867325666180607094856"},{"key":"2026051108191116375_j_acph-2021-0016_ref_034_w2aab3b7c11b1b6b1ab1ac34Aa","doi-asserted-by":"crossref","unstructured":"34. A. Chandwani and J. Shuter, Lopinavir\/ritonavir in the treatment of HIV-1 infection: a review, Ther. Clin. Risk Manag. 4 (2008) 1023\u20131033; https:\/\/doi.org\/10.2147\/tcrm.s328510.2147\/TCRM.S3285","DOI":"10.2147\/TCRM.S3285"},{"key":"2026051108191116375_j_acph-2021-0016_ref_035_w2aab3b7c11b1b6b1ab1ac35Aa","unstructured":"35. J. Dorward and K. Gbinigie, Lopinavir\/ritonavir: A rapid review of effectiveness in COVID-19 (on behalf of the Oxford COVID-19 Evidence Service Team Centre for Evidence-Based Medicine-CEBM); https:\/\/www.cebm.net\/covid-19\/lopinavir-ritonavir-a-rapid-review-of-the-evidence-for-effectiveness-in-treating-covid\/; last access date April 14, 2020"},{"key":"2026051108191116375_j_acph-2021-0016_ref_036_w2aab3b7c11b1b6b1ab1ac36Aa","doi-asserted-by":"crossref","unstructured":"36. B. Cao, Y. Wang, D. Wen, W. Liu, J. Wang, G. Fan, L. Ruan, B Song, Y. Cai, M. Wei, X. Li, J. Xia, N. Chen, J. Xiang, T. Yu, T. Bai, X. Xie, L. Zhang, C. Li, Y. Yuan, H. Chen, H. Li, H. Huang, S. Tu, F. Gong, Y. Liu, Y. Wei, C. Dong, F. Zhou, X. Gu, J. Xu, Z. Liu, Y. Zhang, H. Li, L. Shang, K. Wang, K. Li, X. Zhou, X. Dong, Z. Qu, S. Lu, X. Hu, S. Ruan, S. Luo, J. Wu, L. Peng, F. Cheng, L. Pan, J. Zou, C. Jia, J. Wang, X. Liu, S. Wang, X. Wu, Q. Ge, J. He, H. Zhan, F. Qiu, L. Guo, C. Huang, T. Jaki, F. G. Hayden, P. W. Horby, D. Zhang and C. Wang, A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, N. Engl. J. Med. 382 (2020) 1787\u20131799; https:\/\/doi.org\/10.1056\/NEJMoa200128210.1056\/NEJMoa2001282712149232187464","DOI":"10.1056\/NEJMoa2001282"}],"container-title":["Acta Pharmaceutica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/content.sciendo.com\/view\/journals\/acph\/71\/2\/article-p163.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/acph-2021-0016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T08:27:55Z","timestamp":1778488075000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/acph-2021-0016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,4]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,11,4]]},"published-print":{"date-parts":[[2021,6,1]]}},"alternative-id":["10.2478\/acph-2021-0016"],"URL":"https:\/\/doi.org\/10.2478\/acph-2021-0016","relation":{},"ISSN":["1846-9558"],"issn-type":[{"value":"1846-9558","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,4]]}}}